Browse MMP16

Summary
SymbolMMP16
Namematrix metallopeptidase 16 (membrane-inserted)
Aliases MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ......
Chromosomal Location8q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform Long: Cell membrane Single-pass type I membrane protein Extracellular side Note=Localized at the cell surface of melanoma cells.; SUBCELLULAR LOCATION: Isoform Short: Secreted, extracellular space, extracellular matrix. Cell surface. Note=Localized at the cell surface of melanoma cells.
Domain PF11857 Domain of unknown function (DUF3377)
PF00045 Hemopexin
PF00413 Matrixin
PF01471 Putative peptidoglycan binding domain
Function

Endopeptidase that degrades various components of the extracellular matrix, such as collagen type III and fibronectin. Activates progelatinase A. Involved in the matrix remodeling of blood vessels. Isoform short cleaves fibronectin and also collagen type III, but at lower rate. It has no effect on type I, II, IV and V collagen. However, upon interaction with CSPG4, it may be involved in degradation and invasion of type I collagen by melanoma cells.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001503 ossification
GO:0001958 endochondral ossification
GO:0016485 protein processing
GO:0022617 extracellular matrix disassembly
GO:0030198 extracellular matrix organization
GO:0030574 collagen catabolic process
GO:0032963 collagen metabolic process
GO:0035988 chondrocyte proliferation
GO:0036075 replacement ossification
GO:0043062 extracellular structure organization
GO:0044236 multicellular organism metabolic process
GO:0044243 multicellular organism catabolic process
GO:0044259 multicellular organismal macromolecule metabolic process
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048701 embryonic cranial skeleton morphogenesis
GO:0048704 embryonic skeletal system morphogenesis
GO:0048705 skeletal system morphogenesis
GO:0048706 embryonic skeletal system development
GO:0051604 protein maturation
GO:0060348 bone development
GO:0060349 bone morphogenesis
GO:0060350 endochondral bone morphogenesis
GO:0097094 craniofacial suture morphogenesis
GO:1904888 cranial skeletal system development
Molecular Function GO:0004175 endopeptidase activity
GO:0004177 aminopeptidase activity
GO:0004222 metalloendopeptidase activity
GO:0008047 enzyme activator activity
GO:0008235 metalloexopeptidase activity
GO:0008237 metallopeptidase activity
GO:0008238 exopeptidase activity
GO:0070006 metalloaminopeptidase activity
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005796 Golgi lumen
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1592389: Activation of Matrix Metalloproteinases
R-HSA-1474228: Degradation of the extracellular matrix
R-HSA-1474244: Extracellular matrix organization
Summary
SymbolMMP16
Namematrix metallopeptidase 16 (membrane-inserted)
Aliases MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ......
Chromosomal Location8q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MMP16 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMMP16
Namematrix metallopeptidase 16 (membrane-inserted)
Aliases MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ......
Chromosomal Location8q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MMP16 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMMP16
Namematrix metallopeptidase 16 (membrane-inserted)
Aliases MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ......
Chromosomal Location8q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MMP16 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7810.314
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.2240.36
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4530.68
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.2050.0102
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.1860.364
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.2340.405
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5890.505
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.2420.42
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11122.6940.0899
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1960.763
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1440.865
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1110.55
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MMP16 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141721.45.915.50.304
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103300300.528
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.611.1-8.50.299
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1614014.3-14.30.209
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMMP16
Namematrix metallopeptidase 16 (membrane-inserted)
Aliases MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ......
Chromosomal Location8q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MMP16. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMMP16
Namematrix metallopeptidase 16 (membrane-inserted)
Aliases MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ......
Chromosomal Location8q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MMP16. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MMP16.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMMP16
Namematrix metallopeptidase 16 (membrane-inserted)
Aliases MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ......
Chromosomal Location8q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MMP16. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMMP16
Namematrix metallopeptidase 16 (membrane-inserted)
Aliases MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ......
Chromosomal Location8q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MMP16 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMMP16
Namematrix metallopeptidase 16 (membrane-inserted)
Aliases MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ......
Chromosomal Location8q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MMP16 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMMP16
Namematrix metallopeptidase 16 (membrane-inserted)
Aliases MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ......
Chromosomal Location8q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MMP16 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting MMP16.
ID Name Drug Type Targets #Targets
DB00786MarimastatSmall MoleculeMMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP1 ......23
DB03880BatimastatSmall MoleculeADAM28, ADAMTS5, MMP12, MMP16, MMP85